Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Drug Manufacturers - Specialty & Generic

Healthcare
$4.78 +0.14%

+$0.01 today

Market cap
$791.33M
Beta
0.24
P/E (TTM)
5.6
EPS (TTM)
$0.63
52W Low $0.66High $5.78

Volume 2.22M

Average 2.35M

IRWD Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Ironwood Pharmaceuticals, Inc.NASDAQ: IRWD

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 166.69M shares rose 3.6% year over year, behind the +6.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 6.2% from the prior quarter. Over 3 fiscal years it compounded at -1.6% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +3.6% toward the trailing-twelve-month pace of +6.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
166.69M-6.2% QoQ
Last fiscal yearDec 2025
177.76M+11.0% YoY
LTMMar 2026
170.99M+6.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.6%——
1 year+11.0%——
3-year CAGR-1.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
177.76M USD
Year-over-year change
+11.0%
4-year CAGR
+2.0%

Weighted Avg Shares (Diluted) vs competitors

How IRWD compares with its peers on the latest reported figures

  • IRWD's LTM Mar 2026 weighted avg shares (diluted) of 170.99M shares is the 2nd highest of the 3 companies compared; the peer median is 194.46M shares.
  • Its year-over-year change of +6.8% is the 2nd highest of 3, against a peer median of +78.9%.
  • Over three fiscal years its annual growth of -1.6% compares with a peer median of +90.9%.
IRWD Competitors Peer median
Weighted Avg Shares (Diluted) for IRWD and competitors
Company Period LTM YoY 3-year CAGR
ARDXArdelyx, Inc.LTM Mar 2026242.83M +1.9%+15.0%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026170.99M +6.8%-1.6%
SYRESpyre Therapeutics, Inc.LTM Sep 2026146.1M +155.9%+166.8%
Peer median (excluding IRWD) 194.46M+78.9%+90.9%

Competitors are the stored peer set for IRWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue413.75M410.6M442.74M351.41M296.15M
Cost of Revenue70.41M1.42M6.15M7.55M0
Gross Profit343.35M409.18M436.59M343.86M296.15M
Gross Margin83.0%99.7%98.6%97.9%100.0%
Research & Development70.41M44.27M116.09M111.42M95.14M
Selling, General & Admin0115.99M0082.26M
Operating Expenses111.09M158.84M1.38B250.73M177.39M
Depreciation & Amortization1.52M1.42M1.58M2.01M1.88M
EBITDA233.74M261.44M197.41M97.73M104.65M
EBITDA Margin56.5%63.7%44.6%27.8%35.3%
Operating Income232.26M250.34M(945.43M)93.12M118.76M
Operating Margin56.1%61.0%-213.5%26.5%40.1%
Interest Income726K9.5M18.97M4.47M4.08M
Interest Expense31.15M7.6M21.63M33.03M32.75M
Other Income / Expenses(31.6M)2.09M(2.64M)(27.93M)(48.73M)
Income Before Tax200.66M252.42M(948.07M)65.2M70.03M
Pre-Tax Margin48.5%61.5%-214.1%18.6%23.6%
Income Tax Expense(327.79M)77.36M83.49M64.32M46.01M
Net Income528.45M175.07M(1B)880K24.02M
Net Margin127.7%42.6%-226.4%0.3%8.1%
EPS (Basic)3.261.13(6.45)0.010.15
EPS (Diluted)3.210.96(6.45)0.010.15
Weighted Avg Shares162.25M154.37M155.44M159.08M162.22M
Weighted Avg Shares (Diluted)164.42M186.31M155.44M160.08M177.76M

Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Intrinsic Alpha fair value

Locked

Current Price

$4.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.